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CHAPTER I 
INTRODUCTION 
Alpha-1-acid glycoprotein (AAG) is an acute phase 
protein which plays a role in non-specific immunosuppres-
sion. Serum concentrations of AAG increase during episodes 
of infection or inflammation, and could affect the clinical 
efficacy of drugs by binding to them and inhibiting their 
tissue distribution or in vivo activity. Drugs which are 
organic bases are chiefly bound by AAG and are, therefore, 
most susceptible to the effects of higher serum concentra-
tions of AAG. 
Most infections are not limited to the blood vascular 
system but are located in tissues. Considering that antimi-
crobial agents are inactivated when they are bound to pro-
teins, the concentrations of drug binding proteins in inter-
stitial fluids of tissues and the degree to which drugs are 
bound in interstitial fluids are of considerable relevance 
to in vivo antibacterial efficacy. Unfortunately, the 
interstitial fluid space is relatively inaccessible and 
direct measurement of protein concentrations and drug bind-
ing is difficult. 
Tissue chambers are hollow, perforated devices that 
have been utilized as models to study interstitial fluid and 
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tissue penetration of xenobiotics. After implantation in 
tissue, the chambers form a cavity which is in direct com-
munication with the interstitial space and fills with a 
transudate that is thought to be similar to interstitial 
fluid. Implanted tissue chambers, therefore, provide a 
model which can be used to inves~igate the interactions 
between AAG and drugs in the interstitial space. 
In this study, concentrations of AAG were measured in 
bovine serum and in tissue chamber fluid before and at 
intervals after inoculation of the tissue chambers with 
Pasteurella ~aemolytica .. In addition, parameters describing 
I 
binding of erythromycin in bovine serum and tissue chamber 
fluid and to the pure proteins, AAG and bovine serum albu-
min, were determined. 
CHAPTER II 
LITERATURE REVIEW 
Alpha-1-Acid Glycoprotein 
The liver plays an important role in the systemic 
reaction to tissue injury and inflammation. This reaction, 
termed an acute phase response, is associated with clinical 
conditions such as cancer, arthritis, infection, trauma, and 
surgery. The acute phase response is characterized by an 
increased production and secretion of plasma proteins (>25% 
above normal plasma concentrations), termed acute phase 
proteins (Rosen, 1990; Kushner, 1982). These proteins in-
clude fibrinogen, C-reactive protein, serum amyloid A-pro-
tein, haptoglobin, and a carbohydrate residue-containing 
protein called alpha-1-acid glycoprotein (AAG). 
Physicochemical Properties of AAG 
Glycoproteins consist of carbohydrate side chains 
linked to a central protein core (Winzler, 1960). First 
isolated from serum in 1882 (Landwehr, 1882), AAG was ini-
tially termed seromucoid, owing to the similarities between 
it and a mucoid protein found in eggs (Freund, 1892). More 
recent research, conducted on the human molecules, has 
focused upon characterization (mai'nly determination of 
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molecular weight) and isolation (Freund, 1892; Landwehr, 
1882; Weimer et al, 1950; Schmid, 1955; Bezkorovainy & Win-
zler, 1961) and has resulted in the current designation of 
alpha-1-acid glycoprotein. 
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Studies investigating the molecular characteristics of 
AAG have reported molecu,lar weights ranging from 34,100 
(Kawahara et al, 1973) to 54,000 (Easton et al, 1962). Wide 
differences in observed physical and chemical properties of 
AAG have been attributed to variation in methods of isola-
tion (Alper, 1974; Busby & Ingham, 1986; Hao & Wickerhauser, 
1973) and the degree to which the chosen method affected 
glycosylation of the core protein. Using a two step method 
with adsorption on a diethylaminoethyl (DEAE) Sephadex® 
column and ion-exchange chromatography of the DEAE eluate on 
a carboxymethyl (CM) cellulose column to isolate the native 
molecule, the molecular weight of bovine AAG was determined 
to be 44,100 (Sigma Chemical, St. Louis). 
Several studies have been conducted comparing AAG 
molecules from different species. A study comparing bovine 
AAG with that of humans (Bezkorovainy & Doherty, 1962) re-
vealed only minor differences between the two proteins. 
Findings by Anantha Samy et al (1965) comparing the glyco-
proteins isolated from sheep, goat, cow, buffalo and monkey. 
The proteins exhibited similar properties on electrophore-
sis, ultracentrifugation, and in molecular weight. There 
were differences in chemical composition, mainly in the 
carbohydrate portions. A study has also been reported 
comparing AAG compositlon in the same species, but located 
in different parts of the body. Bezkorovainy (1965) com-
pared AAG from bovine serum, colostrum, and milk whey. The 
AAG molecules from serum and colostrum were very similar, 
but milk contained very small amounts of a carbohydrate 
deficient AAG molecule; 
Effect of Disease on Alpha-1-Acid 
Glycoprotein Concentrations in Humans 
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Numerous studies have reported that patients with 
clinical conditions associated with inflammation have in-
creased serum concentrations of AAG. Harshman et al (1974) 
performed serial AAG assays on samples collected from 213 
patients with cancer. Patients with active metastasis or 
clinical disease exhibited AAG concentrations of up to 240 
mg/dl. Patients in clinical remission had lower AAG serum 
concentrations of between 64 to 86 mg/dl. Mean normal AAG 
concentrations in male and female humans are reported to be 
59.9 mg/dl and 52.4 mg/dl, respectively (Yost & DeVane, 
1985). Arthritis sufferers had serum AAG concentrations of 
149 ± 60 mg/dl, and patients with Crohn's disease (regional 
ileitis) had a mean of 165, as compared with the control 
mean of 66 mg/dl (Piafsky et al, 1978). A study investi-
gating the concentrations of AAG in burn patients revealed a 
mean level of 222 mg/dl, in comparison with a normal of 83 
mg/dl (Bloedow et al, 1982). Trauma patients had increases 
from 70 mg/dl to peak values of 243 mg/dl at 10 to 14 days 
after the insult, and patients suffering from myocardial 
infarction showed increases from 69 ± 9 mg/dl to 181 ± 69 
mg/dl post infarction (Freilich & Gardina, 1984). 
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The prognostic value of AAG concentrations is illus-
trated by the observation that neonates with infections that 
have a poor prognosis have higher serum concentrations (167 
± 67 mg/dl) than those with a favorable prognosis (133 ± 75 
mg/dl). Concentrations of AAG considered normal for human 
neonates vary between i8 ± 8 mg/dl at birth and 52 ± 8 at 2 
days of age (Sann et ~r, 1984). 
Certain diseases may cause decreased AAG serum concen-
tration: liver cirrhosis sufferers have serum AAG concen-
trations that are only 30' of healthy controls, probably due 
to a decreased capacity of the diseased liver to synthesize 
and secrete AAG (Barre et al, 1984). 
Increased AAG production following inflammation is 
mediated via leukocyte endogenous mediator and/or inter-
leukin 1. These cytokines are released by inflammatory 
cells and pass to the liver where they induce transcription 
and synthesis of AAG (Schreiber, 1987). 
Inflammation also leads to endocrine changes which con-
tribute to the acute phase response. In particular, thyroid 
stimulating hormone and thyroxin rates of synthesis are 
increased (Kushner, 1982), resulting in increased levels of 
thyroid hormones, which have a stimulatory effect on AAG 
synthesis. In addition, although steroids inhibit the 
production of interleukin-1 (Ganong, 1989), they have a 
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direct stimulatory effect on the production of AAG (Kulkarni 
et al, 1985). 
Alpha-1-acid glycoprotein is also produced by bovine 
lymphocytes, numbers of which are increased during infection 
and inflammation. However, the relatively small amounts 
(nanograms per million lymphocytes) produced by lymphocytes 
probably contribute little to increased plasma concentra-
tions resulting from inflammatio.n (Iwata et al, 1988a) . 
Alpha-1-acid glycoprotein molecules circulate in the blood 
until the terminal sialic acid is lost, a~d they are then 
taken up by hepatocytes during a single pass through the 
liver (Charlwood et al, 1979). 
Quantitation of AAG 
Several methods have been employed to measure the 
concentration of AAG. Enzyme linked immunosorbant assay 
(ELISA) (Vittinghus, 1990; Freyman et al, 1987) and radial 
immunodiffusion (RID) (Tamura et al, 1989; Iwata et al, 
1988b; Yost & DeVane, 1985; Iwata et al, 1989) have been 
used in several studies to measure AAG serum and urine 
concentrations. Less common methods include rocket electro-
phoresis (Della et al, 1988), nephelometry (Colley et al, 
1983), and precipitation of the protein and detection using 
bicinchoninic (BCA) protein reagent (Conner et al, 1988; 
Conner et al, 1989). The RID method relies on the princi-
ple that molecules smaller than 200,000 M.W. are able to 
diffuse readily through the agarose gel. As the antigen 
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diffuses radially from the well punched in the gel, which 
contains a uniform concentration of a specific antibody, the 
concentration of antigen decreases until an optimal ratio of 
antigen to antibody concentrations is reached, resulting in 
the formation of an antig~n-an~ibody complex and precipita-
tion of that complex. Thus, a precipitin ring is formed 
around the well (Clausen, 1969). Studies revealing a linear 
relationship between the diameter of the precipitin ring and 
the concentration of antigen, without data transformation, 
have been conducted by Mancini et al (1965). 
Function of AAG 
Although many functions of AAG are yet to be elucidat-
ed, some of the activities of AAG that have been identified 
include; inhibition of malaria and erythrocyte interaction, 
transformation of lymphocytes, and inhibition of phagocytic 
activity of macrophages. The carbohydrate portion of the 
molecule apparently interacts with lymphoid cell surfaces, 
leading to non-specific immune suppression (Schrieber, 
1987). 
Binding grogerties of AAG and 
the Effects of Binding on 
Drug Distribution and Efficacy 
AAG binds to a wide range of ligands including endoge-
nous steroids (Ganguly et al, 1967) and xenobiotics (Kremer 
et al, 1988). However, it appears to have a particular 
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affinity for compounds which are organic bases. Unbound 
lidocaine concentration was found to be inversely related to 
the concentration of serum AAG (Routledge et al, 1980; Ed-
wards et al, 1982). Free serum concentrations of many Beta-
adrenocepter drugs decrease in patients with arthritis 
(Belpaire et al, 1982), and methadone free drug concentra-
tions were appreciably lower in patients with cancer than in 
controls (Romach et al, 1982; Abramson, 1982). Meperidine 
binding was studied in maternal and fetal plasma and was 
found to be higher in maternal plasma, which contained 
higher concentrations of AAG (Nation, 1981). Concentrations 
of unbound propranolol were higher in younger patients than 
in older patients. Again, concentrations of AAG were higher 
in the older subjects (Tenero et al, ,1990). Piafsky et al 
(1978) has reported similar results in a previous study, as 
has Abramson et al (1982). A comprehensive review of the 
many studies addressing these correlations has been pub-
lished by Kremer et al, (1988). 
Alpha-1-acid glycoprotein also has affinity for some 
acidic drugs; drugs containing no trace of a carboxyl moiety 
are more likely to bind to AAG than other acidic xenobiotics 
(Urien et al, 1982). 
Several studies have focused on identifying and measur-
ing numbers of binding sites on AAG and the affinity with 
which AAG binds xenobiotics. Research by Westphal & Ashley 
(1962) indicated that estradiol interacted at 3 binding 
sites. In a later study, Kerkey & Westphal (1968) reported 
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that estradiol interacted at 7 binding sites on AAG and that 
cortexone, cortisol, progesterone, and testosterone associ-
ated with a single site. Dette et al (1982) found a single 
primary site of binding for erythromycin binding in humans, 
and in a later study revealed that the primary binding 
protein for erythromycin in human serum was AAG (Dette & 
Knothe, 1986). A recent report characterizing the drug 
binding sites on AAG using florescent probes has demonstrat-
ed that the binding of basic drugs to AAG inhibits the bind-
ing of both basic and acidic probes. Acidic drugs (those 
having a binding affinity for AAG) displaced acidic probes 
from the AAG molecule but did not affect the binding of 
basic probes. These data suggest that there is one binding 
site that interacts with both acidic and basic drugs. Based 
upon these results, Maruyama et al (1990) concluded that AAG 
has a wide binding site, to which both acidic and basic 
molecules bind, and that the regions that bind acidic and 
basic drugs overlap to a significant degree. 
Drug binding becomes a significant factor when consid-
ered in the light of pharmacokinetics. A drug that is bound 
to a serum protein is restricted to the blood vascular 
system. Thus, binding to plasma proteins may affect the 
total body clearance of a drug. Furthermore, there is an 
increasing body of evidence indicating that protein-bound 
xenobiotics are not pharmacologically active (Shoeman et al, 
1973). 
Several techniques have been employed to investigate 
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protein and drug interactions. Techniques available can be 
divided into spectroscopic and non-spectroscopic methods. 
Spectroscopic methods include visible, ultraviolet, and 
florescence spectroscopy along with nuclear magnetic reso-
nance, electron spin resonance, optical rotary dispersion 
dnd circular dichroism~ These methods determine the char-
acteristics of the ligand-macromolecule complex. Non-
spectroscopic techniques include high performance liquid 
chromatography (HPLC), ultracentrifugation, ultrafiltration, 
and equilibrium dialysis. These techniqu~s are based upon 
the determination of the free (unbound) drug concentration 
(Sebille, 1990). The most commonly used methods are HPLC, 
ultrafiltration, and equilibrium dialysis. 
Equilibrium dialysis is, in theory, the most accurate 
way to determine the percentage of binding because the 
equilibrium is not disturbed by shifts in volumes of pro-
tein-free and protein-containing compartments. The semiper-
meable membrane which separates protein-free and protein-
containing compartments allows diffusion of drug molecules 
with molecular weights below a maximum limit. Equilibrium 
or "steady state~' is reached when rates of drug diffusion in 
- ' both directions across the membrane are equal. At this 
stage the amount of free drug is equal in both compartments. 
However, drug bound to protein is sequestered in the protein 
containing compartment. The amount of drug bound to protein 
is determined by measuring the total amount of drug in the 
protein compartment (free plus bound drug) and in the drug 
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compartment (free drug). Since the amount of free drug in 
both compartments is equal, the difference between the 
concentrations of drug present in the two compartments is 
equal to the concentration of drug bound to protein. Param-
eters describing the affinity constant and the number of 
binding sites per molecule can be estimated by a Scatchard 
plot (Scatchard, 1948). A model for analyzing protein-drug 
interaction systems in which the geometric coordinates are 
independent of the concentration of the binding macromole-
cules has been presented by Rosenthal (1967). If protein 
binding is saturated, the affinity constant and the protein 
concentration may be estimated by solving the quadratic 
equation describing the relationship between total and free 
drug concentrations (Borne, 1989). 
Effect of Disease on AAG concentrations 
in Non-human Species 
A study of bovine AAG by Tamura et al (1989) resulted 
in an estimation of molecular weight of 42,000 ± 2,000 and a 
carbohydrate content of 26.6%. 
Iwata et al (1988b) reported that the normal serum 
level of AAG in the adult bovine was 31 ± 9 mg/dl. However, 
concentrations in suckling and yearling animals were slight-
ly lower (25 ± 11 mg/dl and 27 ± 9 mg/dl, respectively) and 
concentrations in fetuses (where the liver is not yet fully 
developed) were even lower (11 ± 4 mg/dl). 
Alpha-1-acid glycoprotein levels in cattle with 
------
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pneumonia averaged 64 ± 45 mg/ml (roughly double the average 
serum concentration), and in those with malignant lymphoma 
had AAG concentrations were as high as 355 mg/dl, 8 times 
the normal serum concentration (Iwata et al, 1988b). Re-
search by Iwata et al (1989) also revealed that serum AAG 
concentrations of bovines suffering from leukemia were 
approximately double normal levels. Another study recorded 
AAG serum concentrations in calves that were infected with 
Pasteurella haemolytica, Ostertagia ostertagi, or adminis-
tered endotoxin. After endotoxin administration, the con-
centration of AAG increased to 150% of the normal levels, 
reaching a peak on day 4. Pasteurella haemolytica infection 
resulted in a doubling of the normal concentrations, with 
peaks occurring on day 4. Ostertagia infections did not 
result in any changes in acute phase· proteins (Conner et al, 
1989) . 
Subcutaneous injection of turpentine causes an acute 
phase response which is similar to that following infectious 
agents. Serum concentration of AAG started increasing on 
day 2 post injection, peaked on day four at roughly 3 times 
the normal level, and then started decreasing, reaching 
normal concentrations by day 17. Concentrations for other 
acute phase proteins, alpha-1-antitrypsin, ceruloplasmin, 
fibrinogen, and haptoglobin were similar to those observed 
in human acute phase responses, with the exception of C-
reactive protein, which is not an acute phase protein in the 
bovine. (Conner et al, 1988). Animals suffering from 
traumatic pericarditis, arthritis, mastitis, pneumonia, or 
mesenteric liponecrosis experienced increases in serum AAG 
concentration of 100%, 100%, 91%, 70%, and 43%, respec-
tively (Tamura et al, 1989). 
14 
Similar observations have been made in species other 
than the bovine. Shibata et al (1977) reported that in rats 
inflammation lead to a 5 to 6 fold increase in- serum AAG. 
In dogs suffering from an inflammatory disease, there was 
again a 5 to 6 fold increase in serum AAG levels (Della et 
al, 1988). 
Tissue Chambers, 
Techniques for Measuring Drug 
Concentration in Tissues 
Except in the case of bacterial infections of the blood 
vascular system, or the cells of the hematopoietic or lym-
phatic system, the majority of infections are located in the 
interstitial spaces of tissues. Thus, it is important to 
have accurate estimates of the concentrations of unbound 
antibiotic drugs in the interstitial space. Methods for 
estimation of the tissue penetration of drugs have been 
reviewed (Clarke, 1989b) and include; skin blisters, skin 
windows, subcutaneous disc model, fibrin clots, fluids from 
body spaces, and exudates from surgical incisions. Skin 
blisters may be induced by suction or by irritants such as 
cantharidin, skin windows are produced by abrading the 
epidermis to expose the dermis, and then allowing 
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equilibrium to be established between paper discs or saline 
filled chambers applied to the abraded dermis. Skin windows 
are similar to the subcutaneous disc model, except that in 
the case of the latter model tissue fluid is sampled from 
subcutaneous tissue instead of the dermal surface. Models 
utilizing fibrin clots involve subcutaneous implantation of 
clots in rabbits to study drug penetration into the tissues. 
These clots have lower peak concentrations and longer elimi-
nation half lives than the corresponding values measured in 
serum. Fluids from body spaces have also been assayed, but 
long diffusional differences and the nature of membranes 
lining the cavities make results from these studies applica-
ble only in cases of infection of the cavities (peritonitis, 
pleuritis, pericarditis, or tenosynovitis). Similarly, 
results from surgical incision exudates are applicable only 
to suture line infections, because bleeding and inflammation 
alter the drug distribution from what it would be in normal 
interstitial spaces. Assay of peripheral lymph has been 
used to give estimates of penetration of drugs into the 
interstitial space. However, problems with penetration of 
protein bound molecules through the lymphatic endothelium, 
changes in lymph flow, and difficulties in cannulation of 
lymphatics can result in unreliable estimates. In addition, 
thoracic duct lymph is unusable because of a high protein 
content (in contrast to the low protein content of intersti-
tial fluid) and the large amounts of material gathered from 
the organs that metabolize and excrete drugs (liver, 
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kidneys, gastrointestinal tract). Tissue homogenates have 
been used to estimate drug penetration. However, homogen-
ates contain blood and intracellular fluid in addition to 
interstitial fluid. Estimates of drug penetration must be 
adjusted to compensate for the presence of the other compo-
nents. However, the technique is appropriate for measure-
ment of drug residues in food animals.· Volume of distribu-
tion is still very commonly used for the estimation of 
penetration of drug outside the blood vascular system. The 
assumption is made that the drug is distributed evenly 
throughout its volume of.distribution, but this is seldom 
the case. For example, aminoglycosides are noted for their 
accumulation in kidneys (Katzung, 1989). Implanted tissue 
chambers have also been used to measure drug penetration 
into the extravascular region, and hav~ the advantage of 
being easy to sample. Multiple chambers can be implanted 
for studies that require frequent sample collection (Ziv et 
al, 1982). 
Construction and Utilization 
of Tissue Chambers 
Tissue chambers are hollow, perforated devices that 
have been constructed o~ various materials including stain-
less steel, plastic (golf 'whiffle' balls), and Delrin®. 
Tissue chambers have been implanted subcutaneously (Short et 
al, 1987), into the peritoneal cavity (Gerding et al, 1976) 
and in organs such as the prostate (Eikenburg et al, 1976b} 
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and the kidney (Eikenburg et al, 1976a). Initially used to 
measure pressures in the interstitial space by Guyton 
(1963), later studies have used the tissue chamber to at-
tempt to estimate drug penetration into the interstitial 
space (Bengsston et al, 1986), to measure the characteris-
tics of microbial growth in vivo (Clarke et al, 1989d), and 
to study the pathophysiology of inflammation (Clarke et al, 
1989a). 
The tissue chamber model used in the current study was 
developed and validated by Clarke and coworkers (1989a; 
1989b; 1989c; 1989d). This perforated thermoplastic tissue 
chamber was constructed of Delrin®, and the open end of the 
shallow cylinder was covered with a silicone rubber membrane 
(Silastic®). After subcutaneous implantation of the cham-
bers in cattle, the chambers fill with blood, inflammatory 
cells, loose fibrin strands, and protein. With the passage 
of time, fibroblasts invade the tissue chamber and begin 
deposition of a loose granulation tissue that becomes more 
organized until it forms a lining of the tissue chamber. 
The fluid inside the tissue chamber immediately after im-
plantation is serosanguinous. With time, the number of 
erythrocytes in the chamber fluid decreases, the concen-
tration of sodium and potassium increases, and the amount of 
protein decreases. Thus, by day 60, the fluid composition 
in the tissue chambers approximates the hypothetical compo-
sition of interstitial fluid (Clarke et al 1989a), making 
the tissue chamber a viable model for pharmacokinetic and 
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other studies. 
Studies using subcutaneously implanted tissue chambers 
to measure the concentrations of oxytetracycline in cattle 
(Bengtsson et al, 1986) and cephapirin in horses (Short et 
al, 1987) concluded that tissue chambers are more suited as 
a model for measuring drug concentrations in regions of 
limited access (abscesses, joint capsules) than as a model 
for the extravascular space of highly perfused tissues. 
Studies conducted by Clarke et al (1989c; 1989d; 1992) 
focused on the use of tissue chambers as a model for study-
ing the effect of ~ haemolytica infection on the tissue 
distribution and in vivo efficacy of antibacterial agents. 
Inoculation of ~ haemoly~ica into tissue chambers implanted 
subcutaneously in cattle results in the establishment of a 
soft-tissue infection model, which can be.used for many 
applications, including the study of protein-drug interac-
tions. 
CHAPTER III 
ASSAY OF ALPHA-1-ACID GLYCOPROTEIN 
Introduction 
Alpha-1-acid glycoprotein (AAG) is an acute-phase 
protein produced by the liver (Schreiber, 1987). Serum 
concentrations of acute-phase proteins increase in response 
to localized inflammation or infection (Kushner, 1982), 
systemic disease states (Harshman et a~1 1967, Kremer et al, 
1989), exposure to toxins (Conner et al, 1988), and trauma 
(Neuhaus et al, 1966). Raised serum levels of AAG have been 
detected in calves following intratracheal inoculation with 
Pasteurella haemolytica (Conner et al, 1989). 
The effect of ~ haemolytica on serum concentrations of 
AAG has important implications with respect to therapeutic 
management of pneumonic pasteurellosis, because the dispo-
sition and therapeutic efficacy of antibacterial agents used 
to treat the infection may be altered. In contrast to 
albumin, which usually binds acidic drugs, AAG binds many 
basic drugs with high affinity (Kremer et al, 1988). Anti-
bacterial agents bound to serum proteins may be prevented 
from distributing to peripheral tissues or may be rendered 
inactive. Since antibacterial efficacy is most closely 
correlated with drug concentrations in the interstitial 
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space, where most infecting bacteria infections are located, 
interstitial concentrations of AAG are of particular inter-
est (Wise et al, 1980, Wise, 1986). 
Subcutaneous tissue chambers have been used to study 
interstitial fluid (Guyton, 1963) and to estimate tissue 
concentrations of antibacterial agents (Bengtsson et al, 
1986). After implantation, these chambers become vascular-
ized by infiltrating granulation tissue. Fluid that accu-
mulates in the chambers is believed to be similar in compo-
sition to interstitial fluid (Clarke et al, 1989a). A soft-
tissue infection model can be established by inoculation of 
~ haemolytica into subcutaneous tissue chambers (Clarke et 
al, 1989c; 1989d; 1992), thus providing a convenient method 
of studying the effect of ~ haemolytica infection on con-
centrations of AAG in tissue fluids. 
Several different methodologies have been employed to 
measure concentrations of AAG, which has a molecular weight 
of 42,000 ± 2000 and a carbohydrate content of approximately 
26% (Tamura et al, 1989). Recently, an accurate radial 
immunodiffusion assay (RID) was used to quantify AAG levels 
in bovine serum. Antiserum used in the RID was obtained by 
immunizing rabbits with AAG purified from bovine serum by 
precipitation, ion-exchange chromatography and gel filtra-
tion (Iwata et al, 1987). Current availability of commer-
cially purified bovine AAG now makes lengthy protein ex-
traction and purification steps unnecessary. 
The objectives of this study were to develop a single 
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radial immunodiffusion assay using commercially prepared AAG 
and to use this assay to measure the concentrations of AAG 
in serum and tissue chamber fluid before and after inocula-
tion of tissue chambers with ~ haemolytica. 
Materials and Methods 
Animals 
Ten Hereford cross-bred calves 4 to 8 months of age and 
weighing from 100 kg to 225 kg were used in this experiment. 
Prior to use, the animals were dewormed with fenbendazole 
(5mg/kg, Safeguard, Hoechst-Roussel) and observed on a daily 
basis during a two week acclimation period to establish that 
they were in good health. The animals were housed in small 
pens and maintained on a 14% protein commercial feed and 
alfalfa hay. 
Implantation of Tissue Chambers 
Two cup-shaped Delrin® (E.I. DuPont Nemours) tissue 
chambers, measuring 46 mm ID and 15 mm in depth, were im-
planted subcutaneously in each calf, one chamber in each 
paralumbar fossa. Perforations in the walls and base of 
the chambers allowed unrestricted exchange of solutes and 
cells between tissue chamber fluid and surrounding intersti-
tial fluids. Chamber fluid could be aspirated by inserting 
a needle through the skin and a silicone rubber (Sialastic®, 
Dow Corning) membrane which covered the top of the chamber. 
Tissue chamber assembly, sterilization, surgical implanta-
tion, and collection of chamber fluid samples have been 
described previously (Clarke et al, 1989b). The sterility 
of the surgical technique was monitored by culturing an 
aspirate of chamber fluid aerobically and anaerobically on 
5% sheep blood agar., 
Study Design 
Approximately 2 months after implantation, pre-inocu-
lation blood and chamber fluid samples were collected and 
all chambers were then inoculated with 1 ml of a 6-hour 
culture of a field isolate of ~ haemolytica serotype 1 
(Corstvet et al, 1973). Inocula were prepared by culture 
on supplemented brain heart infusion agar followed by sus-
pension of the bacteria in phosphate buffered saline (PBS) 
6 
at a concentration of 3 x 10 colony forming units/ml, as 
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previously described (Clarke et al, 1989b). At 2, 4, 6, and 
10 days after inoculation, samples of blood and tissue 
chamber fluid were collected. Serum and tissue chamber 
fluids were frozen at -20°C until the protein assay was 
performed. 
Protein Assay 
Concentrations of albumin in serum and tissue chamber 
fluid were determined using a bromcresol green method 
(Kaplan & Pesce, 1989) (Centrifichem, Baker Instruments) and 
analyzer (Encore, Baker Instruments). 
AAG was assayed by RID. Antiserum to AAG was produced 
in 3 mature female New Zealand White rabbits (Clausen, 
1969). Bovine AAG (Sigma Chemical) was dissolved (100 
ug/ml) in 0.9% saline, the solution was emulsified with an 
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equal volume of adjuvant, and 1 ml of emulsion was injected 
intradermally in multiple sites dorsal to the scapulae of 
each rabbit. Freund's complete adjuvant and Freund's incom-
plete adjuvant were used for the first and for subsequent 
immunizations, respectively. Rabbits were immunized 3 times 
at 2 week intervals, and subsequently every 6 weeks. Every 
6 weeks after the initial immunization up to 50 ml of blood 
was drawn from the central ear artery. Serum was harvested, 
clarified by centrifugation at 25,000 x g, and then filtered 
through a 0.5 urn filter. Antiserum was frozen at -20°C for 
later use. Rabbits were given boosters at 6 week intervals. 
Blood was collected and processed every 2 weeks after subse-
quent immunizations. 
Development of a RID assay followed standard protocols 
(Mancini et al, 1965). Briefly, a 1% solution of agarose 
(Seakem HGT, FMC Bioproducts) was prepared in PBS by heating 
at 80°C with stirring. The agarose was cooled to 50°C, and 
the antiserum was added to a final concentration of 10%. 
Gels were formed by pouring 37.5 ml of agarose/antiserum 
solution on a 125 x 200 mm plate (Gelbond, FMC Bioproducts) 
to a thickness of 1.5 mm. Sample wells (2.5 mm diameter) 
were punched in the gel and 5 ul samples of serum or chamber 
fluid were pipetted into each well. A series of standards 
(0.01, 0.03, 0.1, 0.3, 1, 3 mg/ml) in PBS were included on 
each gel. Gels were incubated in a humid box at 23°C for 72 
hours. After incubation, gels were washed in 3 changes of 
PBS for 72 hours to remove unprecipitated protein followed 
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by 2 washes in deionized water to eliminate PBS. Gels were 
dried and stained (Crowle & Cline, 1977) and the diameters 
of the precipitin rings were measured using a vernier mi-
crometer. 
The purity of commercial bovine AAG was tested using 
SDS-PAGE electrophoresis (Laemmli, 1970) and a Western blot 
(Towbin et al, 1979) was conducted on the rabbit antiserum 
to confirm the specificity of the assay. Intra-assay 
precision,was determined by measuring 5 replicates of 3 
different standard concentrations on the same gel. Inter-
assay precision was calculated by including identical sam-
ples in assays conducted on different gels. Three dilu-
tions of a sample were assayed and compared with the stan-
dard curve to evaluate linearity. Sensitivity was approxi-
mated by estimating the smallest ring size which could be 
reliably measured. Accuracy was estimated by the addition 
of a known amount of AAG (0.1 mg/ml) to serum and comparing 
the spike concentration with the concentration calculated 
using standards. 
Statistical Analysis 
A regression analysis was conducted on successive stan-
dard curve coordinates. Accuracy and linearity were ex-
pressed as percentages. Coefficients of variability were 
used to describe inter- and intra-assay precision. The 
effects of time after inoculation on AAG and albumin concen-
trations in chamber fluid and serum were studied with SY-
STAT, using orthogonal polynomial analysis, adjusted for 
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uneven spacing (Wilkinson, 1987). Protein concentration 
data were also analyzed by the general linear model, block-
ing for calves. Mean concentrations on each of the sampling 
days were then separated using Scheffe's test. Trends were 
considered significant at the P <0.05 level. 
Results 
Log transformation of standard concentrations and ring 
diameters yielded a linear relationship between the highest 
and lowest standard concentrations (Fig. 1 pp. 55). Good 
linearity was demonstrated by close parallelism between the 
standard and sample dilutions. The smallest ring diameter 
which could be accurately measured corresponded to a con-
centration of 0.007 mg/ml .. Inter- and intra-assay coeffi-
cients of variation were 9~39% and 9.48%, respectively, and 
the accuracy of the assay was measured at >90%. 
The pre-inoculatio~ concentrations of AAG in serum and 
chamber fluid (Fig. 2 pp. 56) varied widely between the 
ranges 0.21 - 1.10 and 0.09 - 0.66 mg/ml, respectively. 
Inoculation of tissue chambers caused serum concentrations 
of AAG to increase linearly. Concentrations of AAG in cham-
ber fluids increased quadratically after ~ haemolytica 
infection, with the mean peak concentration occurring at 6 
days. By day'lO, mean AAG concentrations in serum and 
chamber fluid were at least 30% greater than pre-inoculation 
levels (Table 1 pp. 52). Concentrations of albumin in 
chamber fluids increased quadratically after inoculation 
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with~ haemolytica (Fig. 3 pp. 57). However, serum albumin 
concentrations did not change. Utilizing Scheffe's test to 
compare means of AAG and albumin concentrations yielded a 
significant difference in mean concentrations of serum and 
chamber fluid AAG and of chamber fluid concentrations of 
albumin between day 0 (pre-inoculation) and day 4 (peak of 
the post-inoculation samples). Again, serum albumin concen-
trations did not change. Preliminary experiments conducted 
using 2 calves demonstrated that injection of sterile PBS 
into subcutaneous tissue chambers and s~bsequent sampling of 
serum and chamber fluid had no effect on concentrations of 
AAG or albumin in chamber fluid or serum pre-inoculation 
levels. 
Discussion and Conclusions 
Assay of AAG is co~plicated by interspecies variation 
in glycoprotein composition and structure, thus necessitat-
ing development of specific assays ~or each species. Cur-
rent availability of commercially prepared bovine AAG facil-
itates development of such assays, by eliminating the ex-
traction techniques previously required to isolate and 
purify the glycoprotein for preparation of concentration 
standards or production of specific antibodies. The RID 
assay used in the present experiment provided a convenient, 
sensitive, and reproducible method of measuring concentra-
tions of bovine AAG in different biological matrices. 
P. haemolytica is the primary etiological agent of 
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bovine respiratory disease (Jensen et al, 1976), which is 
responsible for considerable economic loss and animal suf-
fering. In the absence of effective vaccines, antibacterial 
therapy remains a major component of control. several of 
the antibacterial agents considered to be effective against 
~ haemolytica, such as erythromycin, are weak organic 
bases. Although basic drugs may associate with several 
plasma constituents, including albumin and lipoprotein, they 
are principally boun~ by AAG (Kremer et al, 1988). Consid-
ering that antibacterial agents are inactivated when they 
are bound to proteins (Wise, 1986) and. that serum concentra-
tions of AAG have been shown to increase dramatically after 
intratracheal inoculation of calves with ~ haemolytica 
(Conner et al, 1989), binding of basic antibacterial agents 
to this acute-phase glycoprotein may reduce in vivo efficacy 
in diseased animals, particularly when drug concentrations 
achieved in the animal are only slightly higher than the 
minimum inhibitory conce~tration. 
Inoculation of ~ haemolytica into subcutaneous tissue 
chambers causes a fibrinopurulent infec·tion with a pathogen-
esis-which is similar to the inflammatory response following 
natural pulmonary infection (Clarke et al, 1989c). In con-
trast to interstitial fluid of pneumonic lungs, subcutaneous 
tissue chamber fluid is easily sampled and can, therefore, 
be used to estimate the concentration of interstitial con-
stituents in~ haemolytica infected tissues. Previous 
experiments have shown that subcutaneous tissue chambers 
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form extracellular interstitial compartments (Clarke et al, 
1989a) and that the composition of chamber fluid approxi-
mates the hypothetical composition of interstitial fluid 
(Clarke et al, 1989d). Concentrations of drug binding 
macromolecules in interstitial fluids are more relevant to 
antibacterial efficacy than blood concentrations because 
most bacterial infections are located in the interstitial 
space. 
The wide intersubject variation in serum and chamber 
fluid AAG concentrations observed in the present study is 
consistent with data reported by Iwata et al (1988a), who 
determined that serum AAG levels in healthy yearling cattle 
varied within the range 0.17 - 0.50 mg/ml. AAG concentra-
tions are affected by many conditions other than bacterial 
infection (Kremer et al, 1988), such as xenobiotics and 
viruses, and it can be assumed that apparently healthy 
animals may be exposed to undetected stimulants of AAG 
production. Furthermore, serum concentrations within indi-
viduals exhibit diurnal variations which may contribute to 
the wide variation in baseline values (Yost and DeVane, 
1985). 
The mean peak serum AAG concentration resulting from 
inoculation of ~ haemolytica into subcutaneous tissue 
chambers (± 50%) was of lower magnitude than that following 
intratracheal inoculation (± 80%)(Conner et al, 1989), al-
though the times taken to achieve maximum concentrations 
were similar (3- 4 days). Subcutaneous injection of oil of 
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turpentine, which had a dose-dependant effect (Conner et al, 
1988), also produced greater increases in serum AAG concen-
tration than tissue chamber inoculation. However, an in-
crease in AAG concentration of 50%, as was observed in the 
present study, may still have a profound effect on the 
degree of drug binding, particularly when the drug is bound 
with high affinity. 
The concentration profile of AAG in chamber fluid was 
similar to that of serum, thus suggesting that AAG in inter-
stitial fluids is derived from serum. Stimulation of the 
acute phase response occurs via interleukins, which induce 
hepatocytes and lymphocytes to synthesize proteins such as 
AAG (Kushner and Mackiewicz, 1987, Iwata et al, 1989b). 
However, lymphocytes were unlikely to be the source of AAG 
in infected tissue chambers 'because ~ haemolytica inocula-
tion causes a neutrophilic response and infected tissue 
chambers contain relatively few lymphocytes (Clarke et al, 
1989b). Furthermore,~ haemolytica infection is known to 
cause erosion of blood vessels in tissue chambers, thus 
disrupting the integrity of the permeability barrier between 
blood and chamber fluid (Clarke et al, 1989a). Under such 
conditions, AAG could easily diffuse from blood into infect-
ed chamber fluid. The rise in chamber fluid albumin concen-
trations after inoculation is further evidence that plasma 
proteins can diffuse into infected tissue chambers. 
In conclusion, ~ haemolytica infection of soft-tissues 
stimulates production of AAG which is reflected by rises in 
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serum as well as tissue chamber concentrations. Higher 
concentrations of AAG and albumin in sites of infection may 
cause an increase in drug binding leading to poor efficacy 
and therapeutic failure. 
CHAPTER IV 
BINDING OF ERYTHROMYCIN 
Introduction 
In vivo antibacterial efficacy is determined by a 
number of factors including the tissue penetration of the 
antibacterial and activity of the antibacterial at the site 
of infection. Binding to serum proteins usually decreases 
the tissue penetration of antibacterial agents because 
protein-bound drugs are too large to pass through capillary 
endothelial layers and are therefore restricted to the 
circulatory compartment, away from the site of most infec-
tions. Furthermore, there is reliable evidence indicating 
that drugs that are protein bound are not pharmacologically 
active (Kunin et al, 1973; Wise et al, 1980). 
Albumin is quantitatively the most important serum 
protein and it's effect on the disposition of acidic anti-
bacterial agents is well established. Although alpha-1-acid 
glycoprotein (AAG) has a high affinity for basic drugs, 
concentrations of this protein in healthy animals are usual-
ly too low to affect drug disposition or efficacy. Conse-
quently, basic drugs (e.g., erythromycin) are usually poorly 
protein-bound in normal animals. However, serum concentra-
tions of AAG may increase considerably during periods of 
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inflammation and/or infection and this may cause an associ-
ated increase in drug binding. During these periods, when 
antibacterial agents are frequently used, AAG-drug interac-
tions may be of therapeutic importance. 
Although binding to serum proteins may affect disposi-
tion and tissue penetration of antibacterial agents, detri-
mental effects of protein binding on antibacterial activity 
are primarily due to drug-protein interactions at the site 
of infection, which is usually the interstitium. Study of 
these interactions is frustrated by an inability to sample 
sufficient quantities of interstitial fluid. Experimental 
infections established by inoculation of subcutaneous tissue 
chambers provide a convenient source of infected tissue 
fluid which can be subjected to in vitro analysis. 
The objective of the study was to determine the effect 
of Pasteurella haemolytica infection on the proportion of 
erythromycin bound to macromolecules in serum and tissue 
fluid and to estimate the binding parameters describing 
binding between erythromycin and bovine AAG and albumin. 
Materials and Methods 
Animals 
Six Hereford cross-bred calves 4 to 8 months of age and 
weighing from 100 kg to 225 kg were used in this experiment. 
Prior to use, the animals were dewormed with fenbendazole (5 
mg/kg, Safeguard, Hoechst-Roussel) and observed on a daily 
basis during a two week acclimation period to establish that 
they were in good health. They were maintained in small 
pens for the duration of the study and were fed grass and 
alfalfa hay supplemented with a commercial grain mixture 
containing 14% protein. 
Implantation of Tissue Chambers 
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Two cup-shaped Delrin® (E.I. Du Pont Nemours) tissue 
chambers, measuring 46 mm ID and 15 mm in depth, were im-
planted subcutaneously in each calf, one chamber in each 
paralumbar fossa. Perforations in the walls and base of the 
chambers allowed unrestricted exchange of solutes and cells 
between tissue chamber fluid and surrounding interstitial 
fluids. Chamber fluid could be as~irated by inserting a 
needle through the skin and the silicone rubber (Silastic®, 
Dow Corning) membrane, which covered the top of the chamber. 
Tissue chamber assembly, sterilization, surgical implanta-
tion, and collection of chamber fluid samples have been 
described previously (Clarke et al, 1989a). The sterility 
of the surgical technique was monitored by culturing an 
aspirate of chamber fluid aerobically and anaerobically on 
5% sheep blood agar. 
Inoculation and Sample Collection 
Approximately 2 months after implantation, preino-
culation blood and chamber fluid samples were collected. 
Five days later, all chambers were inoculated with 1 ml of a 
6 hour culture of a field isolate of ~ haemolytica serotype 
1 (Corstvet et al, 1973). Inocula were prepared by culture 
on supplemented brain heart infusion agar followed by a 
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suspension of the bacteria in phosphate buffered saline 
(PBS) at a concentration of 3 x 106 colony forming units/ml, 
as previously described (Clarke et al, 1989d). Four days 
after inoculation, samples of blood and tissue chamber fluid 
were collected and frozen at -20°C until analysis. 
Dialysis Experiments 
The proportion of erythromycin bound to proteins was 
determined by equilibrium dialysis. Plexiglass® dialysis 
chambers, each containing 8 compartments (200 ul capacity 
each side) were custom constructed. Reconstituted cellulose 
membranes, 0.073 mm thick and with a 6,000 M.W. cutoff (Bel-
Art, Pequannock, NJ), separated protein-free and protein-
containing compartments. Two hundred microliters of sample 
(serum or chamber fluid collected before and 4 days after 
inoculation) were dialyzed for 48 hrs against 200 ml 0.15 M 
phosphate buffer (pH 7.2) containing different concentra-
tions of erythromycin in duplicate (0.5, 5.0 and 50.0 
ug/ml). Equilibrium controls (50 ug/ml erythromycin) were 
included in each assay and were dialyzed for 72 hrs. 
Affinity and capacity binding parameters were determined by 
dialyzing (48 hrs) different concentrations of erythromycin 
(0.5, 5, 20, 40, 60, 80, 100 ug/ml) in phosphate buffer 
against AAG (1 mg/ml) or albumin (3 g/1) in buffer. An 
equilibrium control (100 ug/ml erythromycin) was included in 
each assay and was dialyzed for 72 hrs. 
Desired erythromycin concentrations were obtained by com-
bining a constant amount of labelled erythromycin (0.013 ug 
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of 55 mCi/mmol)(New England Nuclear, Boston, MA) with vary-
ing amounts of unlabelled erythromycin (Sigma Chemical 
Company, St. Louis, MO). Dialysis was performed at 37°C for 
48 hrs (72 hrs for equilibrium controls) in an oscillating 
incubator (Gallenkamp Plus No. 1, Curtin Matheson, Carroll-
ton, TX). After dialysis, the radioactivity of 150 ul aspi-
rated from each compartment was measured by adding 5 ml 
scintillation cocktail (Atomlight®, New England Nuclear, 
Boston, MA) and counting on a liquid scintillation counter 
(LS5000 TDC, Beckman Instruments, Fullerton, CA) for 5 mins. 
Quench correction was achieved by the automatic external 
standard method. 
The stability of erythromycin under dialysis conditions was 
monitored by bioassay, using Micrococcus lutea ATCC 9341 
(Bennett et al, 1966). A 5 ug/ml test standard was divided 
into 20 aliquots; 10 were incubated at 37°C in an oscillat-
ing incubator for 48 hours and the balance were placed in a 
refrigerator at 4°C for the same period. Standard concen-
tration curves were constructed and used to assay the test 
standard, before and after incubation. In addition fresh 
test standard (5 ug/ml) was prepared and assayed concurrent-
ly with the post incubation samples. 
Protein Assay 
Albumin concentrations were assayed using the bromcre-
sol green method and a commercially available chemistry 
analyzer. AAG concentrations were assayed using radial 
immunodiffusion. 
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Data analyses 
The degree of protein binding was calculated using the 
following equation: 
% Binding = 100 X (Act~v~ty on the prote~n-contain~ng s1de - Act~vity on the prote~n-free s1de 
Activity on the prote~n-conta~nlng s~de 
The number of binding sites for erythromycin on AAG was 
determined by Scatchard analysis (Scatchard, 1948), as were 
the initial estimates of binding affinity constants. Bind-
ing parameters of individual data sets were then determined 
by using a microcomputer program (Bourne, 1989} to solve 
quadratic equation describing the relationship between total 
and free drug concentration: 
.[ ~ C (Ka*C -1-Ka*Ptl+ (Ka*C -1-Ka*Ptl +4*Ka*C free = tot ,2 *Katot tot 
where Ka is the binding affinity constant, Pt is the protein 
concentration, and Cfree and Ctot are the total and free drug 
concentrations, respectively (Bevill et al, 1982). Minimum 
sums of weighted residuals (1/cfi_) were approached using 
the Damping Gauss-Newton fitting algorithm. 
The effect of ~ haemolytica on binding of erythromycin 
to serum and chamber fluid were subjected to an analysis of 
variance, blocking for animals and chamber side. 
Results 
Binding of erythromycin to macromolecules in serum and 
chamber fluid ranged from 16% in noninfected chamber fluid 
(50 ug/ml erythromycin) to 55% in serum collected after 
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inoculation (0.5 ug/ml erythromycin) (Table 2 pp. 53). At 
two concentrations of erythromycin (0.5 and 5.0 ug/ml), 
binding in serum was significantly higher after inoculation 
compared with pre-inoculation values. Analysis of variance 
revealed no difference in binding to macromolecules in 
chamber fluids collected before and after inoculation. 
Binding of erythromycin to AAG was saturable between 
the concentrations 0.5 to 100 ug/ml (Table 3 pp. 53) and 
varied between 62% at 0.5 uglmi erythromycin and 27% at 100 
ug/ml erythromycin. Scatchard analysis of data indicated a 
single binding site with a mean binding affinity constant of 
4 4 -1 ' 6.45 X 10 ± 1.65 X 10 M (Fig. 4 pp. 58). Equilibrium 
analysis of the binding using the quadratic equation de-
scribing the relationship between Ctot and Cfree' yielded a 
similar mean estimate of binding affinity (6.91 X 104 ± 3.83 
4 -1 
-5 X 10 M ) at a mean protein concentration of 2.74 X 10 ± 
-5 6.09 X 10 M (Fig. 5 pp. 59). 
Erythromycin was only slightly' bound to albumin (Table 3 pp. 
53) and no specific binding sites could be identified by 
Scatchard analysis. 
Discussion and Conclusions 
Most infections are not limited to the blood vascular 
system, b~'t are more likely to be lo.cated in the intersti-
tium. Therefore, although vascular'drug-protein interac-
tions may affect drug disposition, interactions in tissues 
are most relevant to antimicrobial efficacy. Tissue cham-
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bers have been validated as a model for studying intersti-
tial infections (Clarke et al, 1989a; 1989b; 1989c; 1989d; 
1992) and contain fluid that is thought to be similar to the 
theoretical composition of interstitial fluid. This charac-
teristic and the ease with which these chambers can be 
sampled, makes them convenient models for studying intersti-
tial drug-protein interactions. Furthermore, the chamber 
model allows study of protein binding in infected animals, 
which may be particularly appropriate when a drug interacts 
with acute phase proteins, such as AAG. 
Protein binding at the site of infection may be affect-
ed by several factors including: temperature, pH, drug 
concentration, and protein concentration. Previous studies 
(Chapter III) indicated that inoculation of chambers caused 
increased concentrations of both AAG and albumin in chamber 
fluid and increased concentration of AAG in serum. Thus, 
infection is likely to affect binding of AAG to organic 
bases, such as erythromycin. This was confirmed by the 
results of the present study, in which a higher proportion 
of erythromycin was bound in serum after inoculation than 
before inoculation. Although a similar trend in binding was 
evident in chamber fluid, apparent differences were not 
large enough to be declared statistically significant. 
Assuming saturable binding, the effect of an increase in 
protein concentration has a greater effect on proportional 
binding when drug concentrations are relatively lower. This 
relationship may explain the failure to identify significant 
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differences in binding in chamber fluids which contain less 
protein and relatively more erythromycin or in serum at the 
highest concentration of erythromycin. 
Depending on the drug concentration, erythromycin was 
moderately bound to AAG but only slightly bound to albumin. 
These data are consistent with previous reports indicating 
that AAG is the major binding protein for erythromycin in 
human serum (Dette & Knothe, 1986). Thus, erythromycin 
follows the same pattern as many other basic xenobiotics, in 
that it has a higher affinity for AAG than for albumin, 
which binds acidic molecules more readily (Kragh-Hansen, 
1981; Dette & Knothe, 1986). 
The nonlinear regression analysis served to verify the 
Scatchard analysis and identify the possible existence of 
binding sites other than those on AAG. Close correlation 
between binding affinity constants and protein concentra-
tions confirmed that binding to other macromolecules was 
inconsequential, thus validating the dialysis methodology. 
Furthermore I the nonlinear relationship between ctot and cfree 
confirmed the saturable nature of protein binding at the 
erythromycin concentrations tested. 
In summary, values describing binding of bovine AAG and 
albumin to erythromycin approximate those reported in hu-
mans. Differences in pre- and post-inoculation binding are 
significant at lower and therapeutically relevant concentra-
tions of erythromycin, probably due to increased serum 
concentration of AAG. 
CHAPTER V 
CONCLUSIONS AND SUMMARY 
Inoculation of Pasteurella haemolytica into subcutane-
ous tissue chambers caused an increase in the AAG concentra-
tions in both serum and tissue chamber fluids. A concomi-
tant increase in chamber fluid albumin concentration indi-
cated that the increase in concentration of AAG in tissue 
' 
chambers was due to disruption of capillary endothelial 
barriers. 
At lower relative concentrations of erythromycin, 
binding to serum macromolecules was higher in serum samples 
collected after infection than in those collected prior to 
inoculations. Erythromycin was moderately bound to AAG and 
only slightly bound to album~n. Scatchard analysis of data 
describing binding to pure bovine AAG indicated that eryth-
romycin was bound to a single high affinity site on the pro-
tein. 
A soft-tissue infection, established by inoculation of 
subcutaneous tissue chambers, served as a convenient model 
for studying the effect of infection on drug-protein inter-
actions in interstitial fluid. Although inoculation did not 
cause large increases in the proportion of erythromycin 
bound to chamber fluid or serum proteins, small differences 
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may nevertheless be clinically relevant because tissue 
concentrations of erythromycin often barely exceed minimum 
inhibitory concentrations. 
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TABLE 1 
MEAN (±SD) PERCENT INCREASES IN AAG AND ALBUMIN 
CONCENTRATIONS IN SERUM AND CHAMBER FLUID 
AFTER INOCULATION WITH P. HAEMOLYTICA 
53 
Days after Chamber Fluid Chamber Fluid 
inoculation Serum AAG AAG Albumin 
2 26.6 ± 17.5 40.9 ± 30.8 93.2 ± 66.1 
4 54.9 ± 45.3 95.4 ± 39.1 122.5 ± 80.2 
6 47.0 ± 22.5 103.5 ± 48.7 119.9 ± 97.4 
10 30.6 ± 25.3 70.2 ± 37.4 129.8 ±136.8 
54 
TABLE 2 
MEAN (±SD) PROPORTIONAL BINDING OF ERYTHROMYCIN (0.5, 5, 50 
UG/ML) TO SERUM OR TISSUE CHAMBER FLUID, BEFORE AND 
AFTER INOCULATION OF PASTEURELLA HAEMOLYTICA 
Erythromycin 
Cone Before After 
(ug/ml) inoculation inoculation 
Serum 
0.5 0.48 ± 0.04 0.55 ± 0.02* 
5 0.45 ± 0.03 0.51 ± 0.03* 
50 0.27 ± 0.03 0.29 ± 0.04 
Chamber Fluid 
0.5 0.34 ± 0.04 0.34 ± 0.04 
5 0.32 ± 0.07 0.35 ± 0.03 
50 0.16 ± 0.04 0.19 ± 0.04 
* - Denotes Significant Difference 
TABLE 3 
MEAN (±SD) PROPORTIONAL BINDING OF ERYTHROMYCIN 
TO AAG AND ALBUMIN 
Erythromycin Cone. 
(ug/ml) 
0.5 
5 
20 
40 
60 
80 
100 
AAG 
Percent Bound 
62% 
61% 
51% 
41% 
35% 
29% 
27% 
Albumin 
Percent Bound 
15% 
14% 
13% 
11% 
9% 
8% 
7% 
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Figure 1. Mean (± SD) Logar1thrns of Prec1p1tat1on Ring 
Diameters plotted against Logarithms of AAG 
Concentration Standards. Mean coordinates were 
calculated using Individual Standard Curves for 
each assay (gel) . 
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Significantly Different. 
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Significantly Different. 
8.00E+04 
7.00E+04 
6.00E+04 
,..., S.OOE+04 ::s 
..... 
::s 4.00E+04 z 
3.00E+04 
2.00E+04 
1.00E+04 
0 
0 
+ 
~ 
0 
0 
0 
Ka = 6.45E+04 
n = 1 
..-4 
0 
I 
~ 
0 
I.() 
N 
y = -65698.418x + 74435.178 
r 2 = 0.989 
..-4 ..-4 
0 0 
I I 
~ ~ 
0 0 
0 I.() 
I.() r-
Nu 
59 
0 
0 
+ 
tJ:l 
0 
0 
..-4 
Figure 4. Scatchard Plot of Mean Data describing Binding of 
Erythromycin to AAG. The symbol [u] signifies 
the Free Concentration of Erythromycin and Nu is 
the Ratio of [u] to AAG Concentration. 
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Figure 5. Quadratic Relationship between Free {C-free) and 
Total {C-tot) Concentrations of Erythromycin. 
Plot was constructed using Mean Data. 
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